163212-43-9

Basic information

• Product Name: 2(S)-(4-Methylphenylsulfonamido)-3-[4-oxo-5-[2-(piperidin-4-yl)ethyl]-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-2-ylcarboxamido]propionic acid
• Synonyms: L-738167; N-[(4-methylphenyl)sulfonyl]-3-[({4-oxo-5-[2-(piperidin-4-yl)ethyl]-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-2-yl}carbonyl)amino]-L-alanine
• CAS NO: 163212-43-9
• Molecular Formula: C₂₅H₃₄N₆O₆S
• Molecular Weight: 546.6391
• Mol File: 163212-43-9.mol
• Article Data: 1

Chemical Properties

• Density: 1.48g/cm³
• Refractive Index: 1.686
• CAS DataBase Reference: 2(S)-(4-Methylphenylsulfonamido)-3-[4-oxo-5-[2-(piperidin-4-yl)ethyl]-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-2-ylcarboxamido]propionic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2(S)-(4-Methylphenylsulfonamido)-3-[4-oxo-5-[2-(piperidin-4-yl)ethyl]-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-2-ylcarboxamido]propionic acid(163212-43-9)
• EPA Substance Registry System: 2(S)-(4-Methylphenylsulfonamido)-3-[4-oxo-5-[2-(piperidin-4-yl)ethyl]-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-2-ylcarboxamido]propionic acid(163212-43-9)

Safety Data

• Hazardous Substances Data: 163212-43-9(Hazardous Substances Data)

Usage

General Description

2(S)-(4-Methylphenylsulfonamido)-3-[4-oxo-5-[2-(piperidin-4-yl)ethyl]-5,6,7,8-tetrahydro-4H-pyrazolo[1,5-a][1,4]diazepin-2-ylcarboxamido]propionic acid is a chemical compound with a complex structure. It contains a sulfonamido group, a pyrazolo ring, and a piperidin-4-yl group, among other functional groups. It is likely a synthetic compound with potential pharmaceutical applications, given its long and intricate chemical name. The compound may have potential as a drug or research tool in the field of medicinal chemistry or related areas.

Upstream product

• 163213-77-2 4-(2-{2-[(S)-2-Carboxy-2-(toluene-4-sulfonylamino)-ethylcarbamoyl]-4-oxo-7,8-dihydro-4H,6H-1,5,8a-triaza-azulen-5-yl}-ethyl)-piperidine-1-carboxylic acid tert-butyl ester 
• 622-26-4 4-(2-Hydroxyethyl)piperidine 
• 3112-31-0 3,5-pyrazoledicarboxylic acid 
• 4077-76-3 3,5-dicarbomethoxypyrazole 
• 21753-19-5 2-(S)-p-toluenesulfonylamino-β-alanine 
• 36212-66-5 N²-(toluene-4-sulfonyl)-L-asparagine 
• 89151-44-0 4-(2-hydroxyethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 98-59-9 p-toluenesulfonyl chloride 
• 89151-46-2 tert-butyl 4-(2-iodoethyl)piperidine-1-carboxylate 
• 163213-38-5 methyl [5,6,7,8-tetrahydro-4-oxo-4H-pyrazolo[1,5-a][1,4]diazepin-2-yl]carboxylate 
• 166324-92-1 1-(3-Chloro-propyl)-1H-pyrazole-3,5-dicarboxylic acid dimethyl ester 
• 163213-37-4 dimethyl 1-(3-Azidopropyl)pyrazole-3,5-dicarboxylate 
• 163213-40-9 5-[2-(1-tert-Butoxycarbonyl-piperidin-4-yl)-ethyl]-4-oxo-5,6,7,8-tetrahydro-4H-1,5,8a-triaza-azulene-2-carboxylic acid 
• 163213-39-6 5-[2-(1-tert-Butoxycarbonyl-piperidin-4-yl)-ethyl]-4-oxo-5,6,7,8-tetrahydro-4H-1,5,8a-triaza-azulene-2-carboxylic acid methyl ester 

Relevant articles and documents

Non-peptide glycoprotein IIb/IIIa inhibitors. 17. Design and synthesis of orally active, long-acting non-peptide fibrinogen receptor antagonists

The synthesis and pharmacological evaluation of 5 (L-738,167), a potent, selective non-peptide fibrinogen receptor antagonist is reported. Compound 5 inhibited the aggregation of human gel-filtered platelets with an IC50 value of 8 nM and was found to be >33000-fold less effective at inhibiting the attachment of human endothelial cells to fibrinogen, fibronectin, and vitronectin than it was at inhibiting platelet aggregation. Ex vivo platelet aggregation was inhibited by >85% 24 h after the oral administration of 5 to dogs at 100 μg/kg. The extended pharmacodynamic profile exhibited by 5 appears to be a consequence of its high-affinity binding to GPIIb/IIIa on circulating platelets and suggests that 5 is suitable for once-a-day dosing.